source
- Sanofi beats Q1 sales forecasts, driven by strong Dupixent demandSanofi reported first‑quarter results that exceeded Wall Street expectations, with net sales rising 6.2% to €10.5 billion (about $12.3 billion).\n\nThe growth was led by Dupixent, the anti‑inflamma…
- Novo Nordisk's GLP-1 pill shows blood-sugar reduction in teens with type 2 diabetesNovo Nordisk reported results from a study evaluating its oral GLP-1 therapy, Rybelsus, in adolescents with type 2 diabetes. The trial enrolled participants aged 10-17 who took the pill for roughl…